Mesothelioma is an aggressive cancer that develops in the mesothelium, the thin layer of tissue that lines the lungs, abdomen, heart, and testes. It is almost exclusively caused by exposure to asbestos, a group of naturally occurring mineral fibers that were widely used in construction, insulation, shipbuilding, and manufacturing throughout the 20th century. Despite asbestos regulations in many countries, mesothelioma continues to be diagnosed because of its exceptionally long latency period — typically 20 to 50 years between first exposure and diagnosis.
Approximately 3,000 new cases of mesothelioma are diagnosed annually in the United States. While mesothelioma remains a difficult cancer to treat, significant advances in multimodal therapy, immunotherapy, and precision medicine have extended survival for many patients, and ongoing clinical trials offer hope for further improvements.
Types of Mesothelioma
Pleural Mesothelioma
Pleural mesothelioma accounts for approximately 75–80% of all mesothelioma cases and develops in the pleura (the lining surrounding the lungs). It typically begins as small nodules on the pleural surface that gradually coalesce to form a thick sheet of tumor encasing the lung.
Common symptoms include:
- Shortness of breath (dyspnea), often the earliest symptom
- Chest pain or chest wall pain, typically dull and diffuse
- Persistent cough, usually non-productive
- Pleural effusion (fluid accumulation around the lung) — present in approximately 90% of patients at diagnosis
- Unexplained weight loss and fatigue
- Night sweats
Peritoneal Mesothelioma
Peritoneal mesothelioma accounts for 15–20% of cases and develops in the peritoneum (the lining of the abdominal cavity). Interestingly, peritoneal mesothelioma has a notably better prognosis than pleural mesothelioma, particularly when treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Common symptoms include:
- Abdominal pain and swelling
- Ascites (fluid accumulation in the abdomen)
- Nausea, vomiting, and changes in bowel habits
- Weight loss and loss of appetite
- Abdominal masses
Pericardial Mesothelioma
Pericardial mesothelioma is extremely rare, accounting for less than 1% of cases. It develops in the pericardium (the sac surrounding the heart). Symptoms include chest pain, pericardial effusion, cardiac tamponade, and shortness of breath. Due to its rarity and location, pericardial mesothelioma is frequently diagnosed at autopsy or during surgery for pericardial effusion. Treatment options are limited, and prognosis is generally poor, with median survival of approximately 6 months.
Testicular Mesothelioma
The rarest form, representing less than 1% of cases. It develops in the tunica vaginalis (the lining of the testes). It is often discovered incidentally during hernia repair or hydrocele surgery. Despite its rarity, it tends to have a relatively better prognosis compared to other mesothelioma types when treated with radical orchiectomy.
Histological Subtypes
Mesothelioma is further classified by cell type, which significantly affects prognosis and treatment response:
| Cell Type | Frequency | Characteristics | Median Survival |
|---|---|---|---|
| Epithelioid | ~60–70% | Best response to treatment; most uniform cell pattern | 12–24 months |
| Sarcomatoid | ~10–15% | Most aggressive; resistant to chemotherapy; spindle-shaped cells | 6–8 months |
| Biphasic (mixed) | ~20–30% | Contains both epithelioid and sarcomatoid components; prognosis depends on the proportion of each | 8–15 months |
Asbestos Exposure: Causes and Risk
Asbestos is the primary cause of mesothelioma. The mineral was valued for its heat resistance, tensile strength, and insulating properties. Common sources of exposure include:
Occupational Exposure
- Construction and demolition workers — Asbestos was used in insulation, roofing, floor tiles, cement, and joint compounds
- Shipyard workers — Naval vessels built before the 1980s contained extensive asbestos insulation in engine rooms, boiler rooms, and throughout the ship structure
- Industrial workers — Factories producing asbestos-containing products (brake pads, gaskets, textiles)
- Power plant and refinery workers — Asbestos used for thermal insulation on pipes, boilers, and equipment
- Automotive mechanics — Exposure from brake pads and clutch facings containing asbestos
- Firefighters — Exposure during structural fires in buildings containing asbestos materials
- Military veterans — All branches, particularly Navy veterans, have elevated risk due to widespread asbestos use in military facilities and equipment. Veterans account for approximately 30% of all mesothelioma diagnoses.
Secondary and Environmental Exposure
- Household (secondary) exposure — Family members of asbestos workers exposed to fibers carried home on clothing, hair, and skin
- Environmental exposure — Living near asbestos mines, processing facilities, or naturally occurring asbestos deposits
- Renovation and home improvement — Disturbing asbestos-containing materials in older homes (built before 1980)
Diagnosis
Mesothelioma diagnosis is notoriously difficult because symptoms are nonspecific and overlap with many common conditions. The average time from symptom onset to diagnosis is 3–6 months.
Imaging
- Chest X-ray — Often the first imaging study, may show pleural effusion, pleural thickening, or pleural plaques (calcified markers of prior asbestos exposure).
- CT scan — The primary imaging modality for evaluating the extent of disease. Findings include nodular pleural thickening, pleural effusion, and involvement of the interlobar fissures.
- PET-CT — Used for staging to assess the metabolic activity of pleural thickening and detect distant metastases.
- MRI — Superior to CT for evaluating chest wall, diaphragm, and mediastinal invasion; important for surgical planning.
Tissue Biopsy
A tissue biopsy is required for definitive diagnosis. Cytology from pleural fluid alone is insufficient in most cases (diagnostic in only 30–50% of cases).
- Thoracoscopy (VATS biopsy) — The gold standard for pleural mesothelioma diagnosis. A small camera and instruments are inserted through small incisions in the chest wall to obtain large tissue samples under direct visualization. Allows simultaneous pleurodesis (talc insufflation to prevent fluid reaccumulation) and provides 95%+ diagnostic accuracy.
- CT-guided core needle biopsy — A less invasive alternative, though may yield smaller tissue samples. Diagnostic accuracy of approximately 80–85%.
- Laparoscopy — For peritoneal mesothelioma diagnosis.
Immunohistochemistry
Immunohistochemical (IHC) markers are essential to distinguish mesothelioma from other cancers, particularly lung adenocarcinoma. Key markers include:
- Positive in mesothelioma: Calretinin, WT-1, cytokeratin 5/6, D2-40 (podoplanin), mesothelin
- Negative in mesothelioma (positive in adenocarcinoma): CEA, TTF-1, BerEP4, claudin-4, MOC-31
- BAP1 loss — Loss of BAP1 (BRCA1-associated protein 1) expression by IHC is seen in approximately 60% of mesotheliomas and essentially excludes reactive mesothelial proliferation, making it a useful diagnostic adjunct.
Staging
Pleural mesothelioma is staged using the TNM system (8th edition AJCC). Accurate staging is essential for determining treatment eligibility, particularly for surgery:
| Stage | Description | Median Survival |
|---|---|---|
| Stage I | Tumor confined to the ipsilateral parietal pleura, with or without visceral pleural involvement | ~21 months |
| Stage II | Tumor involving the lung, diaphragm, or mediastinal fat | ~19 months |
| Stage III | Locally advanced: tumor invading chest wall, mediastinal organs, or ipsilateral lymph nodes | ~16 months |
| Stage IV | Contralateral pleura, peritoneum, distant organs, or contralateral lymph nodes | ~12 months |
Surgical Treatment
Surgery for mesothelioma is performed with curative intent (macroscopic complete resection) or palliative intent (symptom relief). Two major surgical approaches exist for pleural mesothelioma:
Extrapleural Pneumonectomy (EPP)
EPP is the more radical procedure, involving removal of the affected lung, the pleura (both parietal and visceral), the ipsilateral diaphragm, and the pericardium. The diaphragm and pericardium are reconstructed with prosthetic patches. EPP aims for maximal tumor removal but carries significant morbidity and mortality (perioperative mortality of 3–7% at specialized centers).
The role of EPP has become more limited following the MARS trial (2011), which suggested that EPP offered no survival advantage over non-surgical management and was associated with higher early mortality. However, some mesothelioma specialists continue to perform EPP in carefully selected patients (epithelioid histology, early stage, good performance status) as part of multimodal protocols.
Pleurectomy/Decortication (P&D)
P&D involves removal of the pleura and all visible tumor while preserving the underlying lung. Extended P&D may include resection of the diaphragm and pericardium without removing the lung. This approach has gained favor due to lower perioperative mortality (1–4%), better preservation of lung function and quality of life, and comparable long-term survival to EPP in recent comparative studies.
The MARS-2 trial, a randomized controlled trial comparing extended P&D plus chemotherapy to chemotherapy alone, reported results in 2024 showing a survival benefit trend for surgical patients, though interpretation continues to be debated.
Surgery for Peritoneal Mesothelioma
Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is the standard treatment for peritoneal mesothelioma and represents one of the most successful treatment paradigms in mesothelioma care. CRS involves removing all visible tumor from the peritoneal surfaces, followed by bathing the abdominal cavity in heated chemotherapy (typically cisplatin at 41–42°C for 60–90 minutes).
Patients with epithelioid histology and complete cytoreduction (CC-0 or CC-1) achieve median survival of 50–60 months, with 5-year survival rates of approximately 50%. These results are substantially better than those for pleural mesothelioma.
Multimodal Treatment
The most effective approach to mesothelioma treatment combines multiple modalities:
Chemotherapy
- Pemetrexed (Alimta) plus cisplatin — The historical standard first-line regimen, based on the landmark Vogelzang trial (2003) that demonstrated improved survival from 9.3 to 12.1 months. Carboplatin is often substituted for cisplatin due to lower toxicity.
- Nivolumab plus ipilimumab — The CheckMate 743 trial (2020) established the combination of nivolumab (PD-1 inhibitor) plus ipilimumab (CTLA-4 inhibitor) as a first-line option, demonstrating improved overall survival compared to chemotherapy (18.1 vs 14.1 months). The benefit was most pronounced in non-epithelioid (biphasic and sarcomatoid) histologies. This represents the first immunotherapy regimen approved for mesothelioma.
Radiation Therapy
- Hemithoracic radiation after EPP — Historically used to sterilize the hemithorax after lung removal. Intensity-modulated radiation therapy (IMRT) allows delivery of tumoricidal doses while sparing the contralateral lung.
- Pleural IMRT after P&D — More challenging due to the presence of the underlying lung, but feasible with advanced planning techniques (proton therapy may offer advantages).
- Prophylactic tract irradiation — Previously used to prevent tumor seeding along biopsy or drain tracts, but the SMART trial showed this is no longer necessary.
- Palliative radiation — For pain control at specific sites of disease involvement.
Emerging Therapies and Clinical Trials
Active areas of mesothelioma research include:
- Tumor treating fields (TTFields) — The STELLAR trial showed improved survival when TTFields were added to pemetrexed/platinum chemotherapy. FDA-approved in the US under the brand name NovoTTF-100L (Optune Lua).
- Gene therapy — Trials using viral vectors to deliver tumor suppressor genes or activate immune responses within the pleural space.
- CAR-T cell therapy — Targeting mesothelin, a protein highly expressed on mesothelioma cells.
- Anti-mesothelin antibody-drug conjugates — Anetumab ravtansine and other agents targeting mesothelin.
- BAP1-directed therapies — Targeting vulnerabilities in BAP1-deficient mesothelioma, including EZH2 inhibitors.
- Combination immunotherapy strategies — Adding VEGF inhibitors (bevacizumab) to immune checkpoint inhibitors.
Legal Resources and Compensation
Because mesothelioma is directly caused by asbestos exposure, patients may be entitled to significant financial compensation. Understanding the legal landscape is important for patients and families navigating the economic burden of this disease.
Asbestos Trust Funds
More than 60 asbestos trust funds have been established by bankrupt asbestos companies under Chapter 11 reorganization, with a combined value exceeding $30 billion. These trusts provide compensation to asbestos exposure victims without the need for a trial. Claims are processed through an administrative review that evaluates the claimant's diagnosis, exposure history, and the trust's specific criteria. Payouts vary by trust and claim type, but mesothelioma claims typically receive the highest compensation levels.
Lawsuits and Litigation
- Personal injury lawsuits — Filed by mesothelioma patients against companies responsible for their asbestos exposure. Average mesothelioma trial verdicts exceed $2 million, with many settlements and verdicts substantially higher.
- Wrongful death lawsuits — Filed by family members after a mesothelioma patient's death.
- Statute of limitations — Varies by state but typically begins from the date of diagnosis (the "discovery rule"). Patients should consult an attorney promptly after diagnosis, as deadlines can be as short as 1–2 years in some states.
Veterans' Benefits
Military veterans diagnosed with mesothelioma may be eligible for VA disability compensation, VA healthcare, and additional benefits. Mesothelioma from military asbestos exposure is recognized as a service-connected condition. Veterans can pursue VA benefits simultaneously with asbestos trust fund claims and litigation.
Prognosis and Survivorship
Mesothelioma prognosis depends on multiple factors including type, histological subtype, stage, patient age, and performance status. Key prognostic indicators include:
- Epithelioid histology — The most favorable cell type, with median survival of 12–24 months. Patients undergoing multimodal treatment may achieve median survival of 2–5 years.
- Peritoneal location with CRS/HIPEC — Median survival of 50–60 months for complete cytoreduction.
- Early stage — Stage I and II pleural mesothelioma patients treated with surgery-based multimodal approaches can achieve 3–5 year survival.
- Good performance status — Patients who are active and able to carry on daily activities have consistently better outcomes across all treatment approaches.
Long-term survivorship (5+ years) is achievable for a subset of patients, particularly those with epithelioid peritoneal mesothelioma treated with CRS/HIPEC and those with early-stage pleural disease treated with multimodal therapy at specialized centers.